Printer-friendly versionMore public and private dollars are being spent to purchase pharmaceuticals for Canadians each and every year. At a time when flattening the health-care cost curve is at the top of many government agendas, the Health Council of Canada is pleased to see the recent attention paid to controlling drug costs and particularly the costs of generic drugs. On Friday, June 18, 2010, The Health Council of Canada released a commissioned discussion paper written by SECOR consulting, Generic Drug Pricing and Access in Canada: What are the Implications?
This independent paper is designed to move the discussion of possible reforms forward on an important part of the drug file – the pricing and distribution of generic drugs - and bring transparency to this important area of public health policy.